Plasmalogens Mediate the Effect of Age on Bronchodilator Response in Individuals With Asthma

Joanne E Sordillo, Sharon M Lutz, Rachel S Kelly, Michael J McGeachie, Amber Dahlin, Kelan Tantisira, Clary Clish, Jessica Lasky-Su, Ann Chen Wu, Joanne E Sordillo, Sharon M Lutz, Rachel S Kelly, Michael J McGeachie, Amber Dahlin, Kelan Tantisira, Clary Clish, Jessica Lasky-Su, Ann Chen Wu

Abstract

Background: Asthma is known to display different phenotypes across the life-course, suggesting that age related changes are particularly relevant to understanding asthma pathogenesis and remission. We have previously demonstrated that a lung function phenotype associated with asthma, bronchodilator response, is reduced with age, at rate of 0.24 percent per year. Methods: In this study, we interrogated the serum metabolome, to determine whether circulating metabolites mediate age-related changes in bronchodilator response (BDR) for individuals with asthma. We used data on 295 participants from the follow-up phase of the CAMP clinical trial (age 12.2-25.9 years; mean BDR of 8%, standard deviation 7%). Using a counterfactual framework, we analyzed over 500 pareto-scaled metabolites using mediation analysis to identify indirect effects of age through potential metabolite mediators. Results: There was a significant indirect effect of age on BDR through 4 plasmalogens (C36:1 PC and related metabolites) (Indirect Effect Beta = -0.001, p = 0.006). Conclusions: Our findings suggest that plasmalogens may contribute to age-related asthma phenotypes, and may also serve as potential pharmacologic targets for enhancement of lung function in individuals with asthma. Trial Registration: This work uses data from the previous clinical trial of asthma, the Childhood Asthma Management Program (CAMP), registered at ClinicalTrials.gov, # NCT00000575.

Keywords: age; bronchodilator response (BDR); interaction; metabolites; plasmalogen.

Copyright © 2020 Sordillo, Lutz, Kelly, McGeachie, Dahlin, Tantisira, Clish, Lasky-Su and Wu.

References

    1. Martinez FD, Vercelli D. Asthma. Lancet. (2013) 382:1360–72. 10.1016/S0140-6736(13)61536-6
    1. Sordillo JE, McGeachie M, Lutz SM, Lasky-Su J, Tantisira K, Tsai CH, et al. . Longitudinal analysis of bronchodilator response in asthmatics and effect modification of age-related trends by genotype. Pediatr Pulmonol. (2019) 54:158–64. 10.1002/ppul.24219
    1. Kelly RS, Virkud Y, Giorgio R, Celedón JC, Weiss ST, Lasky-Su J. Metabolomic profiling of lung function in Costa-Rican children with asthma. Biochim Biophys Acta Mol Basis Dis. (2017) 1863:1590–5. 10.1016/j.bbadis.2017.02.006
    1. The Childhood Asthma Management Program (CAMP): design rationale and methods Childhood Asthma Management Program Research Group. Control Clin Trials. (1999) 20:91–120. 10.1016/S0197-2456(98)00044-0
    1. Imai K, Keele L, Yamamoto T. Identification, inference and sensitivity analysis for causal mediation effects. Stat Sci. (2010) 25:51–71. 10.1214/10-STS321
    1. Imai K, Keele L, Tingley D. A general approach to causal mediation analysis. Psychol Methods. (2010) 15:309–34. 10.1037/a0020761
    1. Steen J, Loeys T, Moerkerke B, Vansteelandt S. Medflex: an R Package for flexible mediation analysis using natural effect models. J Stat Softw. (2017) 76:1–46. 10.18637/jss.v076.i11
    1. Rüdiger M, Kolleck I, Putz G, Wauer RR, Stevens P, Rüstow B. Plasmalogens effectively reduce the surface tension of surfactant-like phospholipid mixtures. Am J Physiol. (1998) 274:L143–8. 10.1152/ajplung.1998.274.1.L143
    1. Wynalda KM, Murphy RC. Low-concentration ozone reacts with plasmalogen glycerophosphoethanolamine lipids in lung surfactant. Chem Res Toxicol. (2010) 23:108–17. 10.1021/tx900306p
    1. Rüdiger M, von Baehr A, Haupt R, Wauer RR, Rüstow B. Preterm infants with high polyunsaturated fatty acid and plasmalogen content in tracheal aspirates develop bronchopulmonary dysplasia less often. Crit Care Med. (2000) 28:1572–7. 10.1097/00003246-200005000-00052
    1. Braverman NE, Moser AB. Functions of plasmalogen lipids in health and disease. Biochim Biophys Acta. (2012) 1822:1442–52. 10.1016/j.bbadis.2012.05.008
    1. Wallner S, Schmitz G. Plasmalogens the neglected regulatory and scavenging lipid species. Chem Phys Lipids. (2011) 164:573–89. 10.1016/j.chemphyslip.2011.06.008
    1. Montoliu I, Scherer M, Beguelin F, DaSilva L, Mari D, Salvioli S, et al. . Serum profiling of healthy aging identifies phospho- and sphingolipid species as markers of human longevity. Aging. (2014) 6:9–25. 10.18632/aging.100630

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren